Skip to main content
. Author manuscript; available in PMC: 2021 May 1.
Published in final edited form as: Cancer Res. 2020 Aug 27;80(21):4854–4867. doi: 10.1158/0008-5472.CAN-20-0384

Figure-7. Candidate HLA-perturbing mutations and immune-response related small molecules.

Figure-7.

(A) The distribution of HLA binding affinity for wild-type (yellow) and mutated peptides (blue) for all NIPPER prioritized genes. ***p<0.001, Wilcox’s rank sum test. (B) The number of mutations that alter binding of HLAs. (C) The 3D structure of candidate mutations in PIK3R1. (D) The relative growth rate of wild-type and mutant PIK3R1 cells in two cell line models. (E) Candidate immune-response related drugs and the corresponding p-values in cancer types predicted by network-based method.